Mintz advised Cardurion Pharmaceuticals on the deal. Cardurion Pharmaceuticals, Inc. (Cardurion), a clinical-stage biotechnology company, announced a private investment of up to $300 million from Bain Capital...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here